Get App

Lupin gets USFDA nod for generic drug

The company has received approval from the US Food and Drug Administration (USFDA) to market its product, a generic version of Bausch Health's Edecrin tablets, in 25 mg strength, Lupin said in a statement.
  • Published On Sep 9, 2019 at 04:34 PM IST
New Delhi: Drug maker Lupin on Monday said it has received approval from the US health regulator to market Ethacrynic Acid tablets, used to treat edema in various conditions, in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market its product, a generic version of Bausch Health's Edecrin tablets, in 25 mg strength, Lupin said in a statement.

As per IQVIA MAT June 2019 data, Ethacrynic Acid tablets had annual sales of around USD 24 million (about Rs 170 crore) in the US.

Shares of Lupin on Monday ended 0.82 per cent lower at Rs 766.20 apiece on the BSE.
  • Published On Sep 9, 2019 at 04:34 PM IST
Be the first one to comment.
Comment Now

COMMENTS

Comment Now Read Comment (1)

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App